| Literature DB >> 19671175 |
Xinxia Peng1, Yu Li, Kathie-Anne Walters, Elizabeth R Rosenzweig, Sharon L Lederer, Lauri D Aicher, Sean Proll, Michael G Katze.
Abstract
BACKGROUND: Hepatitis C virus (HCV) is a major cause of chronic liver disease by infecting over 170 million people worldwide. Recent studies have shown that microRNAs (miRNAs), a class of small non-coding regulatory RNAs, are involved in the regulation of HCV infection, but their functions have not been systematically studied. We propose an integrative strategy for identifying the miRNA-mRNA regulatory modules that are associated with HCV infection. This strategy combines paired expression profiles of miRNAs and mRNAs and computational target predictions. A miRNA-mRNA regulatory module consists of a set of miRNAs and their targets, in which the miRNAs are predicted to coordinately regulate the level of the target mRNA.Entities:
Mesh:
Substances:
Year: 2009 PMID: 19671175 PMCID: PMC2907698 DOI: 10.1186/1471-2164-10-373
Source DB: PubMed Journal: BMC Genomics ISSN: 1471-2164 Impact factor: 3.969
Figure 1Workflow of module identification. 1) Profile expression of both miRNAs and mRNAs in the same set of samples using microarrays. 2) Calculate miRNA-mRNA correlation matrix based on the similarities in the expressions across samples. 3) Estimate false detection rates for a series of thresholds, and choose one based on the desired false detection rate to convert the correlation matrix into a binary miRNA-mRNA correlation network. 4) Construct a miRNA-mRNA regulatory network by combining the constructed miRNA-mRNA correlation network and the corresponding miRNA-target matrix. 5) Represent the regulatory network as a bipartite graph. 6) Enumerate all maximal bicliques as candidate regulatory modules, and post-process candidate modules, including the assessment of both the statistical significances, and differential expressions of target mRNAs between HCV+ and HCV-.
Figure 2Estimated false detection rates associated with different thresholds for miRNA-mRNA expression correlations. The x-axis is a series of thresholds for the Pearson correlation coefficient. The requirement of P < 0.01 was applied for all thresholds at the same time. The y-axis has false detection rates for the corresponding thresholds. The dotted lines indicate that the estimated false detection rate is ~5.7% when the threshold is chosen as Pearson correlation coefficient r < = -0.56 and P < 0.01. For selected thresholds, the numbers aside show the total number of miRNA-mRNA pairs satisfying the corresponding threshold and the estimated false detection rate. The requirement of P < 0.01 alone has estimated false detection rate as ~14% in this dataset.
Genes in HCV associated pathways identified as regulated by miRNAs during HCV infection
| Canonical pathways (IPA) | Predicted target genes | Number of targets |
|---|---|---|
| Chemokine Signaling | SRC, CALM3, CALM2, MAPK6, PPP1CB, KRAS, LIMK2, PTK2, CAMK2D, RRAS2, MAPK14, CCL2, RHOA, CXCL12, CALM1, PRKCB | 16 |
| B Cell Receptor Signaling | MAP2K4, MAP3K14, CALM3, PIK3R1, CALM2, MAPK6, KRAS, INPPL1, PTEN, BCL2L1, CAMK2D, RRAS2, MAPK14, BCL10, PAG1, LYN, PIK3AP1, CALM1, PRKCB | 19 |
| PTEN Signaling | PIK3R1, MAPK6, INPPL1, KRAS, CCND1, PTEN, PTK2, BCL2L1, RRAS2, GHR, BMPR1A, CDKN1A, FASLG | 13 |
| IL-6 Signaling | MAP2K4, IL6ST, MAP3K14, MAPK6, MAP4K4, KRAS, IL1R1, STAT3, COL1A1, IL1F9, RRAS2, MAPK14, MAPKAPK2 | 13 |
| ERK/MAPK Signaling | RAP1B, SRC, PIK3R1, MAPK6, PPP1CB, KRAS, STAT3, PPP2R5A, DUSP2, EIF4E, PLA2G4C, YWHAQ, PTK2, MAPKSP1, RRAS2, ELF3, PRKCB, PRKAR1A | 18 |
| JAK/Stat Signaling | RRAS2, PIK3R1, CDKN1A, SOCS6, MAPK6, KRAS, STAT3 | 7 |
Summary of identified miRNA-mRNA regulatory modules
| mRNA expression in HCV+ vs. HCV-b | Module p-valuec | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Module | No. of mRNA | No. of | miRNA | miRNA | % of overlapped targetsa | log2 ratio | p-value | adj. | P_score | P_Nt | Selected GO terms (BP)d |
| 7 | 48 | 1 | hsa-miR-320 | mir-320 | 56.2 (12.5) | 0.6 | 4.8E-09 | 0.001 | 1.1E-25 | 0 | cell cycle checkpoint |
| 8 | 34 | 1 | hsa-miR-92 | mir-25 | 44.1 (20.6) | 0.6 | 5.6E-10 | 0 | 1.3E-33 | 0 | actin cytoskeleton organization and biogenesis |
| 10 | 77 | 1 | hsa-miR-296 | mir-296 | 62.3 (2.6) | 0.8 | 4.3E-15 | 0 | 5.5E-37 | 0 | T cell receptor signaling pathway |
| 29 | 37 | 1 | hsa-miR-193b | mir-193 | 43.2 (2.7) | 0.6 | 3.9E-08 | 0 | 3.3E-33 | 0 | regulation of apoptosis |
| 30 | 39 | 1 | hsa-miR-181b | mir-181 | 59 (5.1) | 1.0 | 5.8E-24 | 0 | 2.8E-22 | 0.03 | cell cycle checkpoint |
| 37 | 46 | 1 | hsa-miR-422b | mir-378 | 39.1 (2.2) | 0.5 | 6.4E-07 | 0 | 8.1E-26 | 0 | B cell differentiation |
| 39 | 74 | 1 | hsa-miR-122a | mir-122 | 51.4 (1.4) | 0.5 | 1.7E-05 | 0.011 | 1.4E-44 | 0.01 | DNA repair |
| 50 | 11 | 2 | hsa-miR-122a, | mir-122, | 54.5 (0) | 0.8 | 4.9E-13 | 0 | 1.3E-56 | 0 | MAPKKK cascade |
| 87 | 11 | 2 | hsa-miR-193b, | mir-193, | 31.8 (0) | 0.5 | 2.1E-06 | 0.001 | 2.8E-53 | 0 | cell cycle checkpoint |
| 1 | 52 | 1 | hsa-miR-130a | mir-130 | 46.2 (19.2) | -0.5 | 2.3E-05 | 0.016 | 6.5E-15 | 0.02 | regulation of Rho protein signal transduction |
| 2 | 66 | 1 | hsa-miR-26b | mir-26 | 60.6 (13.6) | -0.7 | 3.6E-08 | 0 | 7.9E-32 | 0 | actin cytoskeleton organization and biogenesis |
| 4 | 191 | 1 | hsa-miR-16 | mir-15 | 54.5 (18.3) | -0.8 | 2.5E-09 | 0 | 2.6E-46 | 0 | insulin receptor signaling pathway |
| 13 | 51 | 1 | hsa-miR-21 | mir-21 | 49 (5.9) | -0.6 | 7.6E-07 | 0.002 | 3.8E-33 | 0 | inactivation of MAPK activity |
| 15 | 170 | 1 | hsa-miR-26a | mir-26 | 62.4 (17.1) | -0.6 | 6.4E-07 | 0.002 | 4.8E-50 | 0 | insulin receptor signaling pathway |
| 16 | 22 | 1 | hsa-miR-155 | mir-155 | 54.5 (4.5) | -0.6 | 7.7E-10 | 0 | 4.7E-17 | 0.02 | B cell differentiation |
| 18 | 59 | 2 | hsa-miR-26a, | mir-26 | 62.7 (15.3) | -0.6 | 3.2E-07 | 0.001 | 7.8E-85 | 0 | innate immune response |
| 27 | 86 | 1 | hsa-miR-215 | mir-192 | 43 (1.2) | -0.7 | 1.8E-07 | 0.002 | 8.2E-32 | 0 | insulin receptor signaling pathway |
| 28 | 21 | 2 | hsa-miR-16, | mir-15, | 38.1 (9.5) | -0.7 | 7.0E-09 | 0 | 2.2E-51 | 0 | apoptotic program |
| 36 | 37 | 1 | hsa-miR-324-3p | mir-324 | 45.9 (0) | -0.6 | 2.9E-08 | 0 | 2.6E-07 | 0 | cAMP-mediated signaling |
| 43 | 88 | 1 | hsa-miR-202 | mir-202 | 43.2 (13.6) | -0.6 | 2.3E-04 | 0.036 | 5.6E-52 | 0 | apoptotic program |
| 52 | 82 | 1 | hsa-miR-509 | mir-509 | 50 (1.2) | -0.6 | 1.6E-11 | 0 | 4.8E-60 | 0 | transforming growth factor beta receptor signaling pathway |
| 55 | 48 | 1 | hsa-miR-424 | mir-322 | 60.4 (20.8) | -0.7 | 1.2E-09 | 0 | 1.3E-13 | 0.02 | nuclear import |
| 56 | 30 | 2 | hsa-miR-16, | mir-15, | 53.3 (23.3) | -0.7 | 1.5E-09 | 0 | 1.1E-58 | 0 | transforming growth factor beta receptor signaling pathway |
| 57 | 12 | 1 | hsa-miR-191 | mir-191 | 66.7 (0) | -0.6 | 4.0E-07 | 0.002 | 7.8E-51 | 0 | positive regulation of peptidyl-serine phosphorylation |
| 58 | 15 | 2 | hsa-miR-26a, | mir-26, | 66.7 (23.3) | -0.7 | 2.1E-10 | 0 | 1.4E-44 | 0 | transforming growth factor beta receptor signaling pathway |
| 59 | 19 | 2 | hsa-miR-16, | mir-15, | 60.5 (26.3) | -0.7 | 4.4E-11 | 0 | 2.4E-62 | 0 | transforming growth factor beta receptor signaling pathway |
| 60 | 11 | 3 | hsa-miR-16, | mir-15, | 54.5 (33.3) | -0.7 | 5.3E-12 | 0 | 2.5E-67 | 0 | transforming growth factor beta receptor signaling pathway |
| 63 | 28 | 1 | hsa-miR-199a* | mir-199 | 0 (0) | -0.8 | 5.0E-07 | 0.002 | 2.1E-04 | 0.03 | negative regulation of MAP kinase activity |
| 73 | 12 | 2 | hsa-miR-16, | mir-15, | 66.7 (25) | -0.6 | 2.0E-09 | 0 | 4.2E-55 | 0 | negative regulation of translational initiation |
| 76 | 28 | 2 | hsa-miR-215, | mir-192, | 57.1 (12.5) | -0.6 | 6.7E-07 | 0 | 1.0E-66 | 0 | transforming growth factor beta receptor signaling pathway |
| 78 | 23 | 2 | hsa-miR-130a, | mir-130, | 47.8 (10.9) | -0.4 | 1.3E-07 | 0.001 | 9.6E-63 | 0 | RNA-mediated gene silencing |
| 79 | 35 | 1 | hsa-miR-146b | mir-146 | 68.6 (2.9) | -0.3 | 5.5E-08 | 0 | 4.7E-14 | 0 | complement activation, alternative pathway |
| 81 | 23 | 1 | hsa-miR-15b | mir-15 | 30.4 (8.7) | -0.3 | 2.3E-04 | 0.019 | 6.7E-05 | 0.03 | telomere maintenance via telomerase |
| 94 | 23 | 2 | hsa-miR-202, | mir-202, | 56.5 (6.5) | -0.4 | 4.3E-06 | 0.005 | 2.0E-89 | 0 | transforming growth factor beta receptor signaling pathway |
| 96 | 15 | 2 | hsa-miR-21, | mir-21, | 53.3 (23.3) | -0.5 | 1.7E-08 | 0.001 | 1.6E-51 | 0 | MAPKKK cascade |
| 101 | 11 | 3 | hsa-miR-21, | mir-21, | 54.5 (21.2) | -0.4 | 1.0E-05 | 0.005 | 8.8E-72 | 0 | innate immune response |
| 102 | 10 | 3 | hsa-miR-215, | mir-192, | 53.3 (20) | -0.6 | 5.9E-07 | 0.003 | 1.4E-75 | 0 | endothelial cell migration |
| 170 | 10 | 2 | hsa-miR-202, | mir-202, | 50 (10) | -0.5 | 1.0E-07 | 0.001 | 1.1E-32 | 0 | response to dsRNA |
aThe overlap (%) is with the TargetScan prediction. The number in parenthesis is the overlap (%) with TargetScan conserved predicted targets, i.e. those targets with a conserved site as predicted by TargetScan.
bDifferential expression of target mRNAs in HCV+ vs. HCV- was assessed together as one group for each module. adj. p-value: adjusted p-value, estimated based on 1000 permutations.
cModule p-value was estimated based on 100 simulations. P_score: the scoring method. P_Nt: the counting method.
dOne representative GO term was manually selected for each module. See text for details.
Figure 3Evaluation of direct miRNA regulation of target mRNAs using . A. Heatmap showing inverse expression patterns between miR-16 and its 191 targets (module # 4 in Table 2). Top row shows miR-16 expressions across 30 liver biopsy samples, rows below for its targets. Columns represent samples, identical for both miRNAs and mRNAs. Expressions converted into z-scores. Entry in yellow (blue) indicates expression level of a gene is higher (lower) than mean across all samples. B. Heatmap showing down-regulation of miR-16 targets after transfection into cultured cells. Rows are targets and columns are experiments. The measurements for 181 of 191 targets available, and shown as log2 ratios of 24 h after transfection to mock. Transfections were done with 100 nm miRNAs using HCT116 Dicer-/- cells, the first with 25 nm miRNAs using DLD-1 Dicer -/- cells. In table at the bottom, row 'Mis_match' shows if miR-16 with mismatches used, indicated by locations. 18,19 represents mismatches at positions 18 and 19 of miR-16 mature sequences counted from 5'. 18,19 and 19,20 (2,3 and 4,5) outside (within) seed region. One-sample t-tests (Pval.t for p-values) and non-parametric Wilcoxon tests (Pval.wc) used to assess if overall target expressions shifted after transfection. C. Heatmap showing inverse expression patterns between miR-215 and its 86 targets (module #27 in Table 2), similarly as in (A). D. Heatmap showing down-regulation of miR-215 targets after transfection, similarly as in (B). The measurements for 85 of 86 targets were available. Table at the bottom shows cell types (Cell) and concentrations ('Conc.'). The transfection data was downloaded from GEO: GSM156550, GSM156546, GSM156565, GSM156566, GSM156563, GSM156564 for data shown in (B) from left to right, and GSM156552, GSM156548 in (D). See Linsley et al, 2007 for details.
Figure 4An example of combined analysis of three identified regulatory modules. Schema showing the relationships among module 4, 27, and 28 in Table 2. miRNAs are in red, and mRNA targets are in turquoise (miR-215), or in yellow (miR-215 and miR-16), or in green (miR-16). B. Combined overview of three modules, including miR-215, miR-16, and 86 miR-215 targets and 191 miR-16 targets (21 targets in common). C. An overview of the network expanded from B, by adding protein interaction partners of targets (black dots). Lines indicate protein interaction or miRNA-mRNA regulation. D. A sub-network in (C). Shown are genes in significantly enriched (p-value < 0.01), and HCV associated (manually selected based on literatures) KEGG pathways, including Cell cycle, Apoptosis, P53, MAPK, Insulin, Focal adhesion, Jak-Stat, TGF-beta, Toll-like. Each pathway had at least 10 member genes, including 2 or more predicted targets in (C).